Medpace Holdings (MEDP) EBITDA Margin (2015 - 2026)

Medpace Holdings (MEDP) has reported EBITDA Margin for 12 consecutive years, with 20.98% the latest figure, recorded in Q1 2026.

• EBITDA Margin for Q1 2026 came in at 20.98%, down 54.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 22.04% (down 42.0% YoY), and the FY2025 annual result was 22.22%, down 29.0% from the prior year.
• EBITDA Margin was 20.98% for Q1 2026 at Medpace Holdings, down from 22.61% in the prior quarter.
• Over five years, EBITDA Margin peaked at 24.7% in Q4 2024 and troughed at 18.31% in Q2 2023.
• Average EBITDA Margin over 5 years is 21.05%, with a median of 21.21% recorded in 2024.
• Year-over-year, EBITDA Margin sank 305 bps in 2023 and jumped 589 bps in 2024.
• Over 5 years, EBITDA Margin stood at 20.68% in 2022, then dropped by 9 bps to 18.81% in 2023, then surged by 31 bps to 24.7% in 2024, then retreated by 8 bps to 22.61% in 2025, then slipped by 7 bps to 20.98% in 2026.
• Per Business Quant data, the three most recent EBITDA Margin figures were 20.98% in Q1 2026, 22.61% in Q4 2025, and 22.52% in Q3 2025.